These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24973373)

  • 21. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
    Silva RR; Muniz R; Pestreich L; Childress A; Brams M; Lopez FA; Wang J
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):239-51. PubMed ID: 16768632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above.
    Childress A; Ponce De Leon B; Owens M
    Expert Opin Drug Deliv; 2018 Dec; 15(12):1263-1270. PubMed ID: 30404549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
    Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
    J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
    Coghill D; Banaschewski T; Zuddas A; Pelaz A; Gagliano A; Doepfner M
    BMC Psychiatry; 2013 Sep; 13():237. PubMed ID: 24074240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder.
    Abbas K; Barnhardt EW; Nash PL; Streng M; Coury DL
    Expert Rev Neurother; 2024 Apr; 24(4):421-432. PubMed ID: 38391788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD.
    Childress A; Sallee FR
    Expert Rev Neurother; 2013 Sep; 13(9):979-88. PubMed ID: 24053342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.
    Döpfner M; Gerber WD; Banaschewski T; Breuer D; Freisleder FJ; Gerber-von Müller G; Günter M; Hässler F; Ose C; Rothenberger A; Schmeck K; Sinzig J; Stadler C; Uebel H; Lehmkuhl G
    Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I93-101. PubMed ID: 15322960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating serdexmethylphenidate and dexmethylphenidate capsules as a once-daily treatment option for ADHD.
    Barnhardt EA; Narayanan AR; Coury DL
    Expert Opin Pharmacother; 2023; 24(11):1215-1219. PubMed ID: 37226489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
    Childress AC; Marraffino A; Cutler AJ; Oh C; Brams MN
    J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):51-58. PubMed ID: 36809150
    [No Abstract]   [Full Text] [Related]  

  • 33. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    Paediatr Drugs; 2006; 8(5):319-33. PubMed ID: 17037949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexmethylphenidate.
    Keating GM; Figgitt DP
    Drugs; 2002; 62(13):1899-904; discussion 1905-8. PubMed ID: 12215063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.
    Sayer GR; McGough JJ; Levitt J; Cowen J; Sturm A; Castelo E; McCracken JT
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):882-888. PubMed ID: 27483130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
    Swanson JM; Lerner M; Wigal T; Steinhoff K; Greenhill L; Posner K; Freid J; Wigal S
    J Atten Disord; 2002; 6 Suppl 1():S73-88. PubMed ID: 12685522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.